Teva Pharmaceutical Industries Ltd.

Director's Dealing • Feb 5, 2024

2/4/24, 9:38 PM Ownership Submission

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Weiss Amir	2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited [ TEVA ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _ Director 10% Owner _ X __ Officer (give title below) ___ Other (specify below)
(Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	3. Date of Earliest Transaction (Month/Day/Year) 02/01/2024	Chief Accounting Officer
(Street) Tel Aviv, L3 6944020	4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person
(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security	2. Transaction	2A. Deemed	3. Transaction				4. Securities Acquired (A)	5. Amount of Securities	6.	7. Nature
(Instr. 3)	Date	Execution Date, if	Code		or Disposed of (D)			Beneficially Owned Following	Ownership	of Indirect
	(Month/Day/Year)	any	(Instr. 8)		(Instr. 3, 4 and 5)			Reported Transaction(s)	Form:	Beneficial
		(Month/Day/Year)						(Instr. 3 and 4)	Direct (D)	Ownership
						(A)			or Indirect	(Instr. 4)
						or			(I)
			Code	V	Amount	(D)	Price		(Instr. 4)

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

2/4/24, 9:38 PM		Ownership Submission
Ordinary Shares (1)	02/01/2024	S	31,766	D	\$ 12.3703 (2)	10,676	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Number		6. Date Exercisable			7. Title and	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transaction		of		and Expiration Date		Amount of		Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Derivative			(Month/Day/Year)		Underlying	Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)		Securities				Securities		(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					Acquired					(Instr. 3 and 4)		Owned	Security:	(Instr. 4)
	Security					(A) or							Following	Direct (D)
						Disposed							Reported	or Indirect
						of (D)							Transaction(s)	(I)
						(Instr. 3, 4,							(Instr. 4)	(Instr. 4)
						and 5)
											Amount
								Date	Expiration		or
								Exercisable	Date	Title	Number
				Code	V	(A)	(D)				of Shares

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.37 to \$12.375, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Amir Weiss 02/05/2024

Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

• * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
• ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

**

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

2/4/24, 9:38 PM Ownership Submission

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Weiss Amir	2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited [ TEVA ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _ Director 10% Owner _ X __ Officer (give title below) ___ Other (specify below)
(Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	3. Date of Earliest Transaction (Month/Day/Year) 02/01/2024	Chief Accounting Officer
(Street) Tel Aviv, L3 6944020	4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person
(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security	2. Transaction	2A. Deemed	3. Transaction				4. Securities Acquired (A)	5. Amount of Securities	6.	7. Nature
(Instr. 3)	Date	Execution Date, if	Code		or Disposed of (D)			Beneficially Owned Following	Ownership	of Indirect
	(Month/Day/Year)	any	(Instr. 8)		(Instr. 3, 4 and 5)			Reported Transaction(s)	Form:	Beneficial
		(Month/Day/Year)						(Instr. 3 and 4)	Direct (D)	Ownership
						(A)			or Indirect	(Instr. 4)
						or			(I)
			Code	V	Amount	(D)	Price		(Instr. 4)

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

2/4/24, 9:38 PM					Ownership Submission
Ordinary Shares (1)	02/01/2024		S		31,766	D	\$ 12.3703 (2)	10,676	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Number		6. Date Exercisable			7. Title and	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transaction		of		and Expiration Date		Amount of		Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Derivative		(Month/Day/Year)		Underlying		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)		Securities			Securities			(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					Acquired				(Instr. 3 and 4)			Owned	Security:	(Instr. 4)
	Security					(A) or Disposed of (D)							Following	Direct (D)
													Reported	or Indirect
													Transaction(s)	(I)
						(Instr. 3, 4,						(Instr. 4)	(Instr. 4)
						and 5)
											Amount
								Date	Expiration		or
								Exercisable	Date	Title	Number
				Code	V	(A)	(D)				of Shares

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.37 to \$12.375, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Amir Weiss 02/05/2024

Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

• * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
• ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

**

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.